Evommune

EVMN Lead: Phase 2 4 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-15

Catalyst timeline

EVO301 corporate update2H 2026EVO301 corporate update, 2H 2026, routine
barzolvolimab Celldex Ph3 readout4Q 2026barzolvolimab Celldex Ph3 readout, 4Q 2026, material
EVO756 topline2027EVO756 topline, 2027, major
EVO301 Ph2b startMid-2027EVO301 Ph2b start, Mid-2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (5 active programs)

EVO756

Small Molecule Target: MRGPRX2

Chronic Inducible Urticaria Phase 2 oral NCT06603220
Migraine Phase 2 oral Maruho NCT07616128

EVO301

Protein Target: IL-18, IL-18BP

Atopic Dermatitis Phase 2 intravenous AprilBio
Ulcerative Colitis Phase 2 subcutaneous AprilBio
Atopic Dermatitis Phase 2 subcutaneous AprilBio

Technology platforms

SAFAbody · AprilBio Co., Ltd.

SAFA (Anti-Serum Albumin Fab-Associated) fusion protein platform enabling half-life extension via FcRn-mediated HSA recycling and efficient tissue distribution; used to engineer long-acting IL-18BP therapeutics for inflammatory diseases including atopic dermatitis

Targets: IL-18BP, HSA

Discontinued (2)

EVO756 — Chronic Spontaneous Urticaria · trial did not meet primary endpoint; company decided to cease development of EVO756 for CSU
EVO756 — Atopic Dermatitis · missed primary endpoint in Phase 2b

Biotech Distilled coverage (4)

2026-09-09 UPDATE: Evommune (EVMN) - The Second Shot Misses Too 🔒 Paid
2026-08-07 UPDATE: Evommune (EVMN) - The Clock Moves Up to September 🔒 Paid
2026-06-30 UPDATE: Evommune (EVMN) — The CSU Shot Misses 🔒 Paid
2026-05-22 Evommune (EVMN) — Scientific Deep Dive for EVO756, EVO301 and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.